Evofem Biosciences Enters Material Definitive Agreement
Ticker: EVFM · Form: 8-K · Filed: Aug 20, 2024 · CIK: 1618835
Sentiment: neutral
Topics: material-agreement
Related Tickers: EVFM
TL;DR
EVFM signed a big deal, details TBD.
AI Summary
Evofem Biosciences, Inc. announced on August 16, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details on the agreement or any associated dollar amounts, but it indicates a significant event for the company.
Why It Matters
This filing signals a potentially significant development for Evofem Biosciences, Inc., which could impact its business operations, financial standing, or strategic direction.
Risk Assessment
Risk Level: medium — The lack of specific details in the 8-K filing regarding the material definitive agreement introduces uncertainty and potential risk.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- August 16, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Evofem Biosciences, Inc.?
The filing states that Evofem Biosciences, Inc. entered into a Material Definitive Agreement on August 16, 2024, but does not provide specific details about its nature.
When was the Material Definitive Agreement reported?
The Material Definitive Agreement was reported as of August 16, 2024.
What is the principal executive office address for Evofem Biosciences, Inc.?
The principal executive offices are located at 7770 Regents Road, Suite 113-618, San Diego, California 92122.
What is the telephone number for Evofem Biosciences, Inc.?
The registrant's telephone number is (858) 550-1900.
What was Evofem Biosciences, Inc.'s former company name?
Evofem Biosciences, Inc.'s former company name was Neothetics, Inc., with a date of name change on September 5, 2014.
Filing Stats: 1,699 words · 7 min read · ~6 pages · Grade level 14.6 · Accepted 2024-08-20 16:05:29
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
- $20,000,000 — net proceeds to Parent of no less than $20,000,000. Item 1.01 of this Current Report on
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex2-1.htm (EX-2.1) — 22KB
- 0001493152-24-033265.txt ( ) — 245KB
- evfm-20240816.xsd (EX-101.SCH) — 3KB
- evfm-20240816_lab.xml (EX-101.LAB) — 33KB
- evfm-20240816_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: August 20, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer